HSK3486 Product Profile

The primary mechanism of action for HSK3486 is to increase chloride ion influx through the gamma-aminobutyric acid receptor subtype A (GABAᴀ)-mediated ion channels to achieve central nervous system (CNS) depression
HSK3486 possesses a novel structure analogous to propofol; however, aims to provide clinically meaningful improvements as a result of its modified chemical structure
HSK3486’s structure is unique with a single-configuration R-designation chiral center and a terminal cyclopropyl group. It has been engineered to enhance the pharmacological and physicochemical properties of drug-receptor binding in a systematic manner

Striving to demonstrate improvements of HSK3486 as the next generation anesthetic beyond propofol
- Significant reduction in local pain during injection
- Potentially less respiratory depression, paired with high efficacy, providing an ideal depth of anesthesia

HSK3486 Project Pipeline

To date, 25 Phase I–III clinical studies have been completed in China and Australia
As of October 2020, a total of over 600 subjects have received HSK3486
A Phase III, multicenter, randomized, double-blinded, propofol-controlled study evaluating HSK3486 for induction of general anesthesia in adults undergoing elective surgery has started in the US in Q1 2021 Go to ClinicalTrials.gov
Another replicate Phase III study in the US evaluating HSK3486 for induction of general anesthesia in adults undergoing elective surgery is planned to start in Q3 2022